You are in: eMedicine Specialties > Dermatology > DISEASES OF THE ORAL MUCOSA Noncandidal Fungal Infections of the MouthArticle Last Updated: Sep 23, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Crispian Scully, MD, PhD, BSc, DSc, FRCPath, MRCS, CBE, MDS, FDSRCS, FDSRCPS, FFDRCSI, FDSRCSE, FMedSci, FHEA, FUCL, DChD, DMed(HC), Professor, Dean, Director of Studies and Research, Eastman Dental Institute for Oral Health Care Sciences; Professor, Special Needs Dentistry, University College; Professor, Oral Medicine, Pathology and Microbiology, University of London Crispian Scully is a member of the following medical societies: Academy of Medical Science, British Dental Association, British Society for Oral Medicine, International Association for Dental Research, and Royal Society of Medicine Coauthor(s): Maria Regina Sposto, DDS, PhD, MDSc(Dental Science), PhD(Dentistry), Associate Professor of Oral Diagnosis and Oral Medicine, Professor of Oral Diagnosis and Oral Medicine, Consulting Staff, Department of Oral Surgery and Diagnosis, Faculdade de Odontologia de Araraquara, UNESP-Universidade Estadual Paulista, Brazil Editors: Shyam Verma, MBBS, DVD, FAAD, Adjunct Clinical Assistant Professor, Department of Dermatology, University of Virginia, State University of New York at Stonybrook, Penn State University; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic; Drore Eisen, MD, DDS, Consulting Staff, Department of Dermatology, Dermatology Research Associates of Cincinnati; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System Author and Editor Disclosure Synonyms and related keywords: noncandidal infection of the mouth, fungal mouth infection, mycosis, mycoses, aspergillosis, cryptococcosis, histoplasmosis, blastomycosis, mucormycosis, zygomycosis, paracoccidioidomycosis, Aspergillus flavus, A flavus, Aspergillus terreus, A terreus, Aspergillus fumigatus, A fumigatus, Cryptococcus neoformans, C neoformans, Histoplasma capsulatum, H capsulatum, Blastomyces dermatitidis, B dermatitidis, Mucor species, Rhizopus species, Paracoccidioides brasiliensis, P brasiliensis, cryptococcal meningitis, meningoencephalitis, Gilchrist disease, Gilchrist's disease, Almeida's disease, Almeida disease, rhinosporidiosis INTRODUCTIONBackgroundCandidiasis is the most common fungal infection of the mouth. This article, however, focuses on noncandidal oral fungal infections. A few eMedicine articles on candidiasis include Candidiasis, Chronic Mucocutaneous; Candidiasis, Mucosal; and Candidiasis, Cutaneous. This article discusses 6 noncandidal oral infections: aspergillosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, and mucormycosis. Although these noncandidal fungal infections are considerably less common than oral candidiasis, they commonly produce subclinical infection, especially pulmonary infections. In rare cases, these infections can produce clinical disease in healthy persons. Systemic mycoses in healthy individuals are more common in endemic areas than elsewhere, and they are often asymptomatic and may spontaneously resolve. In otherwise healthy persons, acute pulmonary and primary mucocutaneous symptomatic lesions may resolve without treatment. However, chronic pulmonary infection tends to progress and disseminated infections can be fatal. Immunocompromised persons are at particular risk from these mycoses, and clinical manifestations of infection by these organisms often suggest impaired immune competence.1 Patients at greatest risk include those with leukemia, leukopenia, solid tumors, transplants,2 or HIV disease.3, 4 Also at risk are premature infants. Noncandidal fungal infections have the potential for serious injury to the oral cavity and sometimes also the paranasal sinuses, the orbit, and the cranial base. Orofacial lesions caused by the main systemic mycoses may occasionally be seen in isolation, but they are typically associated with lesions elsewhere, often in the respiratory tract. The oral lesions associated with these deep fungal infections are chronic, may mimic neoplasms, and progress to form solitary, chronic deep ulcers with the potential for local destruction and invasion and systemic dissemination. Chronic oral ulceration, chronic maxillary sinus infection, or bizarre mouth lesions, especially in patients with HIV disease, those with lymphoproliferative disorders, persons with diabetes mellitus, or those who have been in endemic areas, may suggest the diagnosis and patients should be treated in consultation with a physician with appropriate expertise. Most of these mycoses are diagnosed on the basis of a history of foreign travel or an immunocompromised state. Investigations include smears, biopsy, staining with periodic acid-Schiff (PAS) or Gomori methenamine silver, culture of the affected tissues, serodiagnosis (sometimes), physical examination, and chest radiography. Unfortunately, specific immunostaining for an accurate diagnosis of most mycoses is available only in a few laboratories. Definitive diagnosis is achieved by means of microbiologic or histologic identification and serodiagnosis. DNA probes are available for several species. Prompt identification and treatment, usually with systemic antifungal drugs, are essential; delayed treatment or no treatment can result in considerable orofacial destruction, systemic dissemination, or death. Most systemic mycoses can be treated with systemic amphotericin. Azoles are often considered better, but their cost is prohibitive where they are most needed, that is, in the developing world. PathophysiologyAspergillosis More than 160 species and variants of Aspergillus organisms have been discovered, although only 10 are pathogenic in humans. Aspergillus fumigatus is the most common pathogen, but Aspergillus flavus, Aspergillus glaucus, Aspergillus nidulans, Aspergillus terreus, Aspergillus repens, Aspergillus parasiticus, and Aspergillus niger are also encountered. A flavus is the most virulent. Aspergillus species are the most common environmental fungi, being prolific saprophytes in soil and decaying vegetation. Inhalation of the conidia is very likely extremely common, but, unless the inhalation is massive or unless the host is immunocompromised, clinical disease is rare. Nevertheless, aspergillosis is found worldwide. Its prevalence is increasing, and this is the most prevalent mycosis second only to candidosis. The organisms exist as prolific saprophytes in soil and decaying vegetation. Inhalation of the organisms allows for their germination and colonization in the mucosa of the respiratory tract, including the mouth. Lesions may be established primarily in the oral mucosa, but they more commonly begin in the mucosa of the maxillary sinus. They may appear in the oral cavity after local invasion and/or destruction of the surrounding structures. Inhalation of the spores is common, although clinical disease is rare unless the individual is immunocompromised by medication (eg, chemotherapy,5 organ transplantation immunosuppression) or disease (eg, HIV infection, leukemia, lymphoma). Blastomycosis Blastomycosis is a term sometimes used to include a range of granulomatous systemic mycoses, including North American blastomycosis (Gilchrist disease), South American blastomycosis (paracoccidioidomycosis or Almeida disease), coccidioidomycosis, and cryptococcosis. However, the nomenclature is now restricted mainly to the North American and South American forms of blastomycosis, which involve the viscera, lymph nodes, and mucocutaneous tissues. Blastomyces dermatitidis causes the North American form, whereas Paracoccidioides brasiliensis causes the South American form. As expected, North American blastomycosis is seen predominantly in North America, in the Mississippi, Missouri, and Ohio River valleys in the United States and in southern Canada. However, it is also seen in Africa, India, the Middle East, and Australia. B dermatitidis, which is found in soil and spores, may be inhaled to produce respiratory tract and sometimes disseminated disease. Serotype 1 is seen in North America, and serotype 2 is seen in Africa. Outdoor workers are particularly affected, but blastomycosis is increasingly recognized in persons with HIV disease. Coccidioidomycosis Coccidioidomycosis is seen mainly in arid parts of the Western hemisphere, such as the southwestern United States, Mexico, Central America, and parts of South America. Inhalation of spores of Coccidioides immitis, found in soil, produces subclinical infection in up to 90% of the population in such areas. Cryptococcosis Cryptococcosis is seen worldwide in humans and animals. Aspiration of Basidiobolus spores, mainly capsular serotype A but sometimes serotype D of Cryptococcus neoformans (a ubiquitous yeast found especially in pigeon feces and present in soil), may lead to infection. Two varieties have been described, which are C neoformans var neoformans (synonymous with capsular serotypes A, D, and AD) and the less common C neoformans var gattii (synonymous with capsular serotypes B and C). C neoformans var neoformans is found in excreta from pigeons, canaries, parrots, and budgerigars and in rotting fruit and vegetables. C neoformans var gattii is associated with a particular tree, the Red River gum tree (Eucalyptus camaldulensis). Histoplasmosis Histoplasmosis is the most frequently diagnosed systemic mycosis in the United States and has now been reported in approximately 30 countries worldwide. Histoplasma capsulatum, the causal organism, is a soil saprophyte found particularly in northeastern and central states such as Missouri, Kentucky, Tennessee, Illinois, Indiana, and Ohio (mainly in the Ohio and Mississippi valleys). The organism has also been found in Latin America, India, the Far East, and Australia. H capsulatum var duboisii is the type mainly found in equatorial Africa. Histoplasma species are commonly found in bird and bat feces. In endemic areas, the organism is a soil saprophyte, and more than 70% of adults appear to be infected, typically with subclinical manifestations, as a result of inhaling spores. Mucormycosis6 Mucor and Rhizopus species are the most common agents to cause zygomycosis. Fungi of the order Mucorales (of the class Zygomycetes) are responsible for most mucormycosis. However, in addition to Mucor and Rhizopus species, organisms from the genera Absidia, Apophysomyces, Mortierella, Saksenaea, Rhizomucor, and Cunninghamella may also be involved. Therefore, the condition is probably better termed zygomycosis. These fungi are ubiquitous worldwide in soil, manure, and decaying organic matter. Classic zygomycosis occurs worldwide. In some warmer regions, other Zygomycetes such as Conidiobolus coronatus infect a range of animals and can also occasionally cause rhinofacial zygomycosis in humans. Most human cases have been recorded from the Caribbean, Latin America, and Central and West Africa. Mucoraceae are commonly cultured from the nose, throat, mouth, and feces of many healthy individuals, but infection is virtually unheard of in otherwise healthy individuals. Paracoccidioidomycosis South American blastomycosis (paracoccidioidomycosis or Almeida disease) is found mainly in Colombia, Venezuela, Uruguay, Argentina, and particularly Brazil. In Brazil, the disease is endemic in the states of Sao Paulo, Rio de Janeiro, and Minas Gerais. P brasiliensis is responsible and is presumably being inhaled as spores. Subclinical infection is not uncommon in endemic areas. FrequencyUnited StatesBecause of the ubiquitous presence of these fungi in the environment, exposure is common. However, clinical disease is uncommon except in persons with iatrogenic or pathologic immunosuppression. InternationalBecause of the ubiquitous presence of these fungi in the environment, exposure is common in endemic areas, and travelers may present with manifestations even years after exposure. However, clinical disease is uncommon except in persons with iatrogenic or pathologic immunosuppression. Mortality/MorbidityIn a healthy individual, infection is typically self-limited, although latency is commonly established, rather than elimination. Reactivation of latent infection may subsequently occur if the infected individual becomes immunosuppressed.
RaceThe deep mycoses can affect individuals of all races; no racial predilection is recognized. SexThe mycoses affect both sexes equally. AgeThe deep mycoses can affect individuals of all ages, although they are more common in adults than in children. Elderly individuals may be at increased risk, although this is often secondary to impaired immunity. CLINICALHistoryThe following conditions may predispose individuals to infection. These conditions require an evaluation to determine whenever a deep fungal infection is established.
PhysicalPatients with deep mycoses may present with a primary infection of the oral mucosa, but, more commonly, they present with an extension of an established paranasal infection. Therefore, by the time oral lesions are present, considerable destruction of the maxilla and maxillary sinus may have occurred. In healthy individuals, the disease is usually self-limiting, but in individuals who are immunocompromised, extensive local destruction, fungemia, visceral and cerebral invasion, and death are substantial risks. The most common presentation of oral deep fungal infection is a chronic, solitary ulcer or nodule. When infection involves the palate, this finding may be only the initial indication of considerable antecedent destruction of the maxilla and maxillary sinus. Extension and/or invasion into the orbital and cranial cavity are not uncommon. The condition may be indistinguishable from other causes of chronic oral ulcers (eg, tuberculosis, malignancy).
Causes
DIFFERENTIALSAspergillosis Bacillary Angiomatosis Cancers of the Oral Mucosa Candidiasis, Chronic Mucocutaneous Candidiasis, Mucosal Hand-Foot-and-Mouth Disease Herpes Simplex Kaposi Sarcoma Leukoplakia, Oral Noncandidal Fungal Infections of the Mouth Oral Examination Oral Manifestations of Systemic Diseases Squamous Cell Carcinoma Syphilis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Amphotericin B (Amphocin, Fungizone) |
|---|---|
| Description | Polyene antibiotic produced by a strain of Streptomyces nodosus; can be fungistatic or fungicidal. Binds to sterols, (eg, ergosterol) in the fungal cell membrane, causing intracellular components to leak, with subsequent fungal cell death. |
| Adult Dose | 0.3-1.5 mg/kg/d IV |
| Pediatric Dose | 0.25-1.5 mg/kg/d IV |
| Contraindications | Documented hypersensitivity |
| Interactions | Antineoplastic agents may enhance the potential of amphotericin B for renal toxicity, bronchospasm, and hypotension; corticosteroids, digitalis, and thiazides may potentiate hypokalemia; risk of renal toxicity is increased with cyclosporine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Monitor renal function, serum electrolytes (eg, magnesium, potassium), liver function, CBC counts, and hemoglobin concentrations; resume therapy at lowest level (eg, 0.25 mg/kg) when therapy is interrupted for > 7 d; hypoxemia, acute dyspnea, and interstitial infiltrates may occur in patients with neutropenia receiving leukocyte transfusions (separate time of amphotericin infusion from time of leukocyte transfusion); fever and chills are not uncommon after first few administrations; nephrotoxicity, thrombophlebitis, thrombocytopenia, anemia, and hypokalemia may occur; rare acute reactions may include hypotension, bronchospasm, arrhythmias, and shock |
| Drug Name | Caspofungin (Cancidas) |
|---|---|
| Description | Used to treat refractory invasive aspergillosis. First of a new class of antifungal drugs (glucan synthesis inhibitors). Inhibits synthesis of beta-(1,3)-D-glucan, an essential component of the fungal cell wall. |
| Adult Dose | 50 mg IV qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with cyclosporin may increase risk of hepatotoxicity; carbamazepine, nelfinavir, efavirenz, or dexamethasone may decrease levels; may decrease levels of tacrolimus |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in moderate hepatic dysfunction (decrease dose); may exacerbate preexisting renal dysfunction or myelosuppression; hepatotoxicity, hypokalemia, and blood dyscrasia may occur |
| Drug Name | Flucytosine (Ancobon) |
|---|---|
| Description | Converted to fluorouracil after penetrating fungal cells. Inhibits RNA and protein synthesis. Active against Candida and Cryptococcus species and is generally used in combination with amphotericin B. Treats aspergillosis. |
| Adult Dose | 50-150 mg/d PO in divided doses q6h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; impaired renal or hepatic function |
| Interactions | Amphotericin B may increase toxicity; cytosine may inactivate; along with rifampin, increases activity of amphotericin B |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in bone marrow suppression; adjust dose in renal impairment; hepatotoxicity, hypokalemia, blood dyscrasia, hypoglycemia, or cardiopulmonary arrest may occur |
| Drug Name | Fluconazole (Diflucan) |
|---|---|
| Description | Fungistatic activity. Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal cytochrome P-450 and sterol C-14 alpha-demethylation, which prevents conversion of lanosterol to ergosterol, thereby disrupting cellular membranes. |
| Adult Dose | 200 mg/d PO/IV |
| Pediatric Dose | 6-12 mg/kg/d PO/IV |
| Contraindications | Documented hypersensitivity |
| Interactions | Levels may increase with hydrochlorothiazides; levels may decrease with long-term coadministration of rifampin; may increase concentrations of theophylline, phenytoin, tolbutamide, cyclosporin, glyburide, and glipizide; may increase effects of anticoagulants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose for renal insufficiency; closely monitor if rashes develop, and discontinue drug if lesions progress; may cause clinical hepatitis, cholestasis, and fulminant hepatic failure (including death) when taken with underlying medical conditions (eg, AIDS, malignancy) or while taking multiple concomitant medications; not recommended for mothers who are breastfeeding; hepatotoxicity and leukopenia may occur |
| Drug Name | Ketoconazole (Nizoral) |
|---|---|
| Description | Fungistatic activity. Imidazole broad-spectrum antifungal; inhibits synthesis of ergosterol, causing cellular components to leak and resulting in fungal cell death. |
| Adult Dose | 200 mg/d PO 200-400 mg/d PO, with food or soda |
| Pediatric Dose | 5-10 mg/kg/d PO |
| Contraindications | Documented hypersensitivity; fungal meningitis |
| Interactions | Isoniazid may decrease bioavailability; coadministration decreases effects of rifampin or ketoconazole; may increase effect of anticoagulants; may increase toxicity of corticosteroids and cyclosporine (can adjust cyclosporine dosage); may decrease theophylline levels; decreases metabolism of repaglinide, increasing serum levels and effects |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May reversibly decrease corticosteroid serum levels (adverse effects avoided with dose of 200-400 mg/d); administer antacids, anticholinergics, or H2-blockers at least 2 h after taking; hepatotoxicity, leukopenia, and thrombocytopenia may occur |
| Drug Name | Miconazole (Monistat IV) |
|---|---|
| Description | Damages fungal cell wall membrane by inhibiting biosynthesis of ergosterol. Membrane permeability is increased, causing nutrients to leak and resulting in fungal cell death. Interferes with mitochondrial enzymes. |
| Adult Dose | 400-1200 mg IV q8h |
| Pediatric Dose | 5-40 mg/kg/d IV q8h |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Fever, chills, rash, itching, anorexia, thrombocytopenia, cardiac arrest, and anemia may occur |
| Drug Name | Itraconazole (Sporanox) |
|---|---|
| Description | Fungistatic activity. Synthetic triazole antifungal agent that slows fungal cell growth by inhibiting cytochrome P-450–dependent synthesis of ergosterol, a vital component of fungal cell membranes. |
| Adult Dose | 50-400 mg/d PO Alternatively, 200 mg/d IV |
| Pediatric Dose | 5 mg/kg/d IV |
| Contraindications | Documented hypersensitivity |
| Interactions | Antacids may reduce absorption; edema may occur with coadministration of calcium channel blockers (eg, amlodipine, nifedipine); hypoglycemia may occur with sulfonylureas; may increase tacrolimus and cyclosporine plasma concentrations when high doses are used; rhabdomyolysis may occur with coadministration of HMG-CoA reductase inhibitors (eg, lovastatin, simvastatin); coadministration with cisapride can cause cardiac rhythm abnormalities and death; may increase digoxin levels; coadministration may increase plasma levels of midazolam or triazolam; phenytoin and rifampin may reduce levels (phenytoin metabolism may be altered) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in hepatic insufficiencies; hepatotoxicity and hypokalemia |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Oslei Paes de Almeida, MD, to the development and writing of this article.
| Media file 1: Aspergillosis. Note deep mucosal ulceration and nodular expansion of the hard palate. Courtesy of David Sirois, DMD, PhD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Blastomycosis. Top image shows nonspecific papillary nodular lesion on the hard palate. Bottom image shows extensive ulceration involving the skin of the face and neck. Courtesy of David Sirois, DMD, PhD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Histoplasmosis. Top image shows periodontal recession and deep ulceration with exposed necrotic alveolar bone (arrow). Bottom image shows solitary, deep ulceration of the gingivae also associated with necrotic bone (arrow). Courtesy of David Sirois, DMD, PhD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 4: Mucormycosis. Top left image shows multiple, deep ulcerations (arrows) of the hard palate. Top right image shows destruction of the palate and the floor of the orbit (failed skin graft of the right eye after orbital enucleation); this infection originated in the maxillary sinus. Bottom image shows similar deep, destructive ulceration of the left posterior maxillary alveolar bone and mucosa due to mucormycosis of the maxillary sinus. Courtesy of David Sirois, DMD, PhD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 5: Cryptococcosis. Left image shows solitary, destructive lesion resulting in necrosis of alveolar bone and palatal mucosa; note the superficial pseudomembranous candidiasis of the palate. Right image shows nonspecific chronic ulceration of the buccal mucosa due to cryptococcosis; this is associated with submucosal induration and regional adenopathy. Courtesy of David Sirois, DMD, PhD. | |
![]() | View Full Size Image | Media type: Photo |
Noncandidal Fungal Infections of the Mouth excerpt
Article Last Updated: Sep 23, 2008